Clobetasol propionate
- Generic Name
- Clobetasol propionate
- Brand Names
- Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32ClFO5
- CAS Number
- 25122-46-7
- Unique Ingredient Identifier
- 779619577M
- Background
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974.
Clobetasol Propionate was granted FDA approval on 27 December 1985.
- Indication
Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
- Associated Conditions
- Alopecia, Severe Plaque psoriasis, Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis, Moderate Plaque psoriasis, Moderate Scalp Psoriasis, Severe Scalp Psoriasis
Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus
- Conditions
- Oral Lichen Planus
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- University of Peradeniya
- Target Recruit Count
- 68
- Registration Number
- NCT02744378
A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 240
- Registration Number
- NCT02733874
Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea
- Conditions
- Scleroderma
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT02680717
Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus
- Conditions
- Vulvar Lichen Sclerosus
- Interventions
- Device: Fractionated Carbon Dioxide Laser
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 52
- Registration Number
- NCT02573883
- Locations
- 🇺🇸
Medstar Washington Hospital Center Lafayette Office, Washington, District of Columbia, United States
Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser
- Conditions
- Vulvar Lichen Sclerosus
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Daniela de Fátima Teixeira da Silva
- Target Recruit Count
- 30
- Registration Number
- NCT02416531
- Locations
- 🇧🇷
Hospital Pérola Byington, São Paulo, SP, Brazil
A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
- Conditions
- Skin Tissue DiseasesConnective Tissue Diseases
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT02392130
- Locations
- 🇩🇪
bioskin GmbH, Hamburg, Germany
A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Glaxal Base cream vehicle
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT02376049
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
🇮🇱Beit Harofim, Netanya, Israel
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
- Conditions
- Stage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IIIC Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7Stage IIIA Colorectal Cancer AJCC v7Colon AdenocarcinomaRectal AdenocarcinomaStage III Colorectal Cancer AJCC v7Stage IIIB Colorectal Cancer AJCC v7
- Interventions
- Other: Pharmacological StudyOther: Quality-of-Life Assessment
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 123
- Registration Number
- NCT02368886
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid
- Conditions
- Bullous Pemphigoid
- Interventions
- Procedure: Impedance analysis
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 35
- Registration Number
- NCT02360202
- Locations
- 🇫🇷
Rouen University Hospital, Rouen, France
A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
- Conditions
- Skin and Connective Tissue Diseases
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT02355639
- Locations
- 🇩🇪
Charité - Universitaetsmedizin Berlin, Department of Dermatology and Allergy, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.